Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

Share this content:
In this review, researchers identified 7 economic studies that evaluated the cost of AEs among patients with advanced melanoma.
In this review, researchers identified 7 economic studies that evaluated the cost of AEs among patients with advanced melanoma.

The direct financial costs of managing adverse events (AEs) associated with systemic therapies for patients with advanced melanoma are significant, according to a study published in Medicine

There are various treatment modalities for advanced melanoma, including chemotherapy, interleukin-2, interferon, and biochemotherapies, each associated with separate safety profiles. The financial burden associated with managing these AEs have not been fully explored. 

For this systematic literature review, researchers identified 7 economic studies conducted between 2007 and 2017 that evaluated the cost of AEs among patients with advanced melanoma. Selected studies assessed direct costs and healthcare resource utilization, including hospitalizations, medication use, and physician visits. The studies were done in multiple countries, and primarily assessed the estimated costs for grade 3 to 4 adverse events. 

In a US study, results showed that monthly costs for AE management accounted for 36.9% of overall healthcare costs for dacarbazine, 30.3% for paclitaxel, 9.2% for temozolomide, 6.4% for vemurafenib, and 4.0% for ipilimumab. 

A multicountry study revealed that grade 3 to 4 AEs associated with the greatest cost per event were ipilimumab-associated colitis (Australia, France) and diarrhea (United Kingdom), and chemotherapy-induced neutropenia/leukopenia (Germany, Italy). 

Overall, the most significant source of financial burden for AEs were hospitalizations and use of outpatient medications/procedures, such as erythropoietin and blood transfusions for anemia. 

The authors concluded that “the costs of managing each AE associated with the treatment of advanced melanoma are substantial but may be reduced by effective treatments with improved safety profiles.”

Reference

Copley-Merriman C, Stevinson K, Liu FX, et al. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature reviewMedicine. 2018;97(31):e11736.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs